VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047.
The company said its BiTAC platform is designed to improve the selectivity and safety of cancer therapies by activating treatments only when multiple tumor-associated targets are present. VERAXA also highlighted proprietary click chemistry, conjugation, linker and payload technologies intended to enhance the safety, efficacy and manufacturability of its antibody-drug conjugate and T-cell engager pipelines, reinforcing its long-term strategy to develop next-generation oncology therapeutics.
This expansion marks a significant milestone for VERAXA as it seeks to establish a dominant position in the competitive oncology landscape. By securing intellectual property rights for its BiTAC platforms, the company aims to create a moat around its technology, potentially blocking competitors from using similar approaches. The patents cover not only the therapeutic designs but also the underlying manufacturing processes, which could lower production costs and improve scalability.
Analysts view the patent portfolio expansion as a key driver for VERAXA’s valuation, as it provides clarity on the company’s freedom to operate and potential licensing opportunities. The protection through 2047 offers a long runway for commercialization, assuming the therapies gain regulatory approval. VERAXA’s pipeline includes several preclinical and clinical-stage candidates targeting various solid tumors and hematologic malignancies.
The company’s BiTAC technology is particularly noteworthy for its conditional activation mechanism, which could reduce off-target toxicity—a common challenge in cancer immunotherapy. By requiring multiple tumor markers for activation, the therapy may spare healthy cells, potentially leading to better patient outcomes and fewer side effects. This approach aligns with the broader industry trend toward precision medicine.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company continues to build on that foundation, leveraging its proprietary technologies to advance its pipeline of ADCs and BiTAC formats into clinical development.
For more details, the full press release is available at https://ibn.fm/BqhFS. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
